Life Edit

by

Vic Myer, Ph.D. is a seasoned scientific leader with more than 25 years of research and development experience. A former CSO and CTO, he currently advises by sitting on two Boards of Directors, four Scientific Advisory Boards, is an advisor to the NIH SCGE, and is an advisor to Atlas Venture. His most recent role was President and Chief Scientific Officer at Chroma Medicine where he helped build that epi-genetic editing company from concept to successful proof of concept in NHPs with a clear path to the clinic. Previously, he was Chief Technology Officer of Editas Medicine where he led the genome editing platform, CMC and chemistry departments. At the Novartis Institutes for Biomedical Research, he led a large, technology focused target discovery, target validation and lead finding group in the Developmental and Molecular Pathways department for 11 years. Prior to Novartis, Vic focused on industrializing and using ‘omics technologies at Millennium, Akceli and Corning. He has B.S. from Cornell, a Ph.D. from Yale and did his post-doc at MIT/The Whitehead Institute.

by

David Hallal is the CEO, Chairman, and co-founder of ElevateBio, Life Edit’s parent company. He is a 30-year veteran in the biopharmaceutical industry with expertise in early-stage company building as well as operating large multinational biotech companies. He also is Chairman of AlloVir.

Prior to ElevateBio, David spent more than a decade at Alexion Pharmaceuticals as Chief Executive Officer, Chief Operating Officer, and Chief Commercial Officer and played a central role in transforming the company from the pre-commercial stage in 2006 to greater than $3 billion in annual revenues by 2016. As the CEO of Alexion, David transitioned the company from a single product to a multi-product enterprise. This included the US, EU, and Japan approval and the highly successful launch of Strensiq® and the rapid advancement of Alexion’s highest value pipeline candidate, Ultomiris, from a preclinical stage to registration trials in multiple diseases in just 18 months.

David also served as Alexion’s Chief Commercial Officer and then Chief Operating Officer, where he built the company’s commercial infrastructure and a 50-country operating platform which launched Soliris® for two ultra-rare diseases, Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome, resulting in the most successful commercialization of an ultra-orphan drug in the biotechnology industry.

Prior to Alexion, David held commercial leadership positions at biopharmaceutical companies where he launched and expanded the adoption of numerous first-in-class and blockbuster products in hematology, oncology, nephrology, immunology, and ophthalmology, as the Vice President of Sales at OSI Eyetech and at Biogen where he led the immunology sales team. Prior to Biogen, David has also held various leadership roles at Amgen focused on the major oncology and hematology products Epogen®, Neupogen®, Neulasta®, and Aranesp®.

David serves as the Chairman of Scholar Rock (Nasdaq: SRRK), Chairman of iTeos Therapeutics, and is an independent director of Seer Biosciences. David is also an advisor at MPM Capital. He holds a B.A. in Psychology from the University of New Hampshire.

by

Dr. Mitchell Finer serves as a Strategic Advisor for ElevateBio, Life Edit’s parent company, and focuses his efforts on changing the way medicine is practiced through the development of ex vivo and in vivo gene edited products leveraging Life Edit’s RNA guided nuclease and base editing platform. He is a co-founder of ElevateBio and previously served as the Company’s President of Research & Development and as Chief Executive Officer of Life Edit. Additionally, Dr. Finer is an executive partner at MPM Capital.

Dr. Finer led ElevateBio’s R&D efforts, and was instrumental in the scaling of its technologies, expanding of its manufacturing capabilities and capacity, and driving the Company’s growth as a technology-driven organization. Prior to joining ElevateBio, he served as Chief Scientific Officer of Bluebird Bio, where he led the team that conceived of and developed three approved products: Abecma for the treatment of multiple myeloma, Zynteglo for the treatment of beta thalassemia and Skysona for the treatment of childhood cerebral adrenoleukodystrophy. He has served as founder, executive officer or board member at multiple cell therapy, gene therapy and regenerative medicine companies over the last 33 years, including Adverum Biotechnologies, Bluebird Bio, Coda Biotherapeutics, Cell Genesys, the Gencell division of Aventis Pharma (now Sanofi), Genteric, Inc., Intracel Corporation, Novacell (now Viacyte, acquired by Vertex), Oncorus, Inc., Semma Therapeutics, Turmeric Acquisition Holdings, and TCR2 Therapeutics.

His efforts have spanned discovery through market launch of cell gene therapy and regenerative medicine products in the U.S., Europe and Asia. He has also worked on many of the innovations for manufacture of these products.

by

Vikas Sinha is the Chief Financial Officer and co-founder of ElevateBio, Life Edit’s parent company. He brings more than 25 years of experience in executive finance roles in the life sciences industry and also serves as President and Chief Financial Officer of AlloVir.

Prior to ElevateBio, Vikas served as CFO of Alexion Pharmaceuticals for 11 years, where he was responsible for finance, business development, strategy, and IT. During his tenure as CFO, Alexion’s market cap grew from $600 million to more than $30 billion and revenue grew from zero to more than $3 billion.

‍Prior to joining Alexion, Vikas held various positions with Bayer AG in the United States, Japan, Germany, and Canada, including Vice President and CFO of Bayer Pharmaceuticals Corporation, U.S. and VP and CFO of Bayer Yakuhin Ltd., in Japan. He serves as an independent board member and Audit Committee Chair of Verona Pharma Inc.

Vikas received his MBA from the Asian Institute of Management, Manila, Philippines. He is a qualified Chartered Accountant and associate member of the Institute of Chartered Accountants of India and a Certified Public Accountant in the United States.